NCT06775886Terminated
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Reason given: PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.
Brief summary (registry, in English)
This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber implantable cardioverter defibrillators (ICD) systems. Patients will be randomly assigned to either personalized accelerated pacing (using the myPACE+ algorithm with mono-fractional exponent) or usual care groups. At baseline and after 3 months of pacing all patients will undergo a CPET, echocardiogram, blood work for NT-proBNP levels and complete the KCCQ-OSS and HCMSQ, questionnaires. The investigator team hypothesizes that personalized accelerated pacing will be safe and improve symptoms and heart-failure related quality of life, physical activity, pVO2, biomarkers (i.e. NT-proBNP), diastolic parameters and cardiac structure.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 9 Jan 2025
- Start date
- 2 Oct 2025
- Primary completion date
- 23 Oct 2025
- Lead sponsor
- Montefiore Medical Center
- Diseases
- Hypertrophic cardiomyopathy, Heart failure
- NCT number
- NCT06775886
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant primary pulmonary disease on home oxygen
- Uncontrolled hypertension as defined by BP >160/100 mmHg on two measurements ≥15 minutes apart
Lab values
- LVEF <50%
Other
- Pregnancy
- LVOT gradient > 30mmHg at rest or with provocation
- Prolonged PR > 250ms
- Baseline RV-pacing burden of > 1% more than moderate valvular stenosis or regurgitation
- Aortic valve replacement in the past one year
Who the study is looking for
- Non obstructive HCM: Left Ventricular Outflow Tract (LVOT) gradient <30mmHg at rest and with provocation
- Left ventricular ejection fraction (LVEF) ≥50%
- New York Heart Association (NYHA II-III) symptoms
- Normal intrinsic conduction system
- Suitable dual-chamber implantable cardioverter defibrillators (ICD) system
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montefiore Medical Center | The Bronx | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.